Latest news with #DepartmentofHealth-AbuDhabi
Al Etihad
06-07-2025
- Health
- Al Etihad
Abu Dhabi to welcome top-tier physicians from US, South Korea, Australia this July
7 July 2025 00:59 SAMIHAH ZAMAN (ABU DHABI)Abu Dhabi will once again welcome several leading physicians in a bid to offer expert healthcare and medical services within the to Abu Dhabi as part of the Department of Health- Abu Dhabi (DoH) Visiting Physicians Programme , the doctors will provide medical care and advice in plastic surgery, paediatric oncology, ophthalmology, and spine care.'The DoH welcomes top-tier doctors from around the world to the Emirate during July, offering exceptional healthcare services through the Visiting Physicians Programme,' the DoH announced on its social media Michael Grimley, paediatric haematologist-oncologist at Cincinnati Children's Hospital, US, is one of the quartet of doctors heading to the UAE capital this month. Dr. Grimley specialises in the care of anaemia, sickle cell disease, haemophilia, leukaemia, and lymphoma. He will see patients at the Sheikh Khalifa Medical City between July 7-11, Geelen, ocularist at the Artificial Eye Services Hospital in Perth, Australia, will see patients at Moorfields Eye Hospital between July 13 -17, 2025. Geelen has more than two decades of experience in the making and fitting of hand crafted artificial Zeeshan Sardar, associate chief of spine and scoliosis surgery at the New York Presbyterian Hospital, US, will meanwhile be available at Healthpoint Hospital between July 28 and August 1, 2025. Dr. Sardar is an expert in the treatment of adult scoliosis, ankylosing spondylitis, complex spine surgery, and degenerative spine Joon Pio Hong, consultant plastic surgeon at Asan Medical Center, South Korea, has also offered medical care for lymphoedema, lipoedema, and diabetic foot at Abu Dhabi's Tarmeem Hospital and Healthpoint Hospital this DoH has urged patients and their families to book appointments with the experts by contacting the respective health care in 2021 with the aim of providing top-notch healthcare within Abu Dhabi, the Visiting Physicians Programme has enabled more than 300 surgeries, and seen the contribution of more than 30 visiting experts from around the world. As of December 2024, more than 3,200 patients had received treatment and consultation in Abu Dhabi as part of the initiative. Source: Aletihad - Abu Dhabi
Gulf Today
05-07-2025
- Health
- Gulf Today
DoH advances paediatric cell and gene therapy
The Department of Health - Abu Dhabi (DoH) has signed a strategic Memorandum of Understanding with Children's National Hospital in Washington, D.C., to establish the Abu Dhabi - Children's National Hospital Cell and Gene Therapy Clinical Excellence Programme. The partnership marks a major step in advancing access to paediatric cell and gene therapies across the UAE. The agreement outlines joint fellowships, training programmes and workshops aimed at developing local expertise, positioning Abu Dhabi as a global hub for innovation in life sciences. Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, said the partnership reflects Abu Dhabi's integrated, patient-centred approach to healthcare. She added, "By combining global expertise with local ambition, we are building a care model that is sustainable, scalable and tailored to the needs of our youngest patients." Michelle Riley-Brown, President and CEO of Children's National, said the collaboration builds on a long-standing partnership with the UAE, aiming to fast-track the development of cutting-edge therapies and offer new hope to children and families. The initiative will drive development and delivery of advanced therapies such as Virus-Specific T-cell therapies (VST), with plans to establish Good Manufacturing Practices (GMP) compliant facilities, standardise treatment protocols, and streamline clinical trial systems in Abu Dhabi. The agreement also covers joint biobanking, data governance improvements and long-term patient care integration. A major component includes Emirati clinician-scientist fellowships and the co-development of specialised training in cellular immunotherapy and trial management. The partnership will introduce virtual tumour board sessions and hands-on training in cell therapy manufacturing, quality control, and clinical procedures. Complementary workshops will focus on Investigator-Initiated Trials (IITs) and regulatory design, strengthening Abu Dhabi's healthcare workforce. The agreement follows a high-level Abu Dhabi delegation visit to the United States from 15th to 21st June, 2025, focused on health innovation and investment. Participants included the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, NYU Abu Dhabi, Khalifa University, MBZUAI and startAD. WAM
Al Etihad
25-04-2025
- Health
- Al Etihad
Department of Health – Abu Dhabi advances precision medicine for Alzheimer's
25 Apr 2025 14:20 The Department of Health - Abu Dhabi (DoH), in collaboration with M42 Biogenix Lab, has taken a groundbreaking step in personalised healthcare by integrating APOE E4 genetic testing into its pharmacogenomics (PGx) first-of-its-kind innovative approach in the region ensures that healthcare providers can assess a patient's genetic risk and personalise Alzheimer's treatments to ensure safer and more effective disease is a progressive neurological condition characterised by memory loss, cognitive decline and behavioural changes. According to the World Health Organization, Alzheimer's is the leading cause of dementia worldwide. Globally, there are over 10 million new cases of dementia each year, equating to one new case every 3.2 inclusion of the APOE E4 genotyping in the pharmacogenomics reports is a result of collaboration between The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and M42's Biogenix Lab. It represents a significant milestone in precision treated with anti-amyloid monoclonal antibodies, as one of the therapeutic options, Alzheimer's patients with two copies of APOE E4 may experience severe side effects, such as brain swelling or bleeding. Therefore, by identifying these genetic risks, clinicians can tailor Alzheimer's treatment plans for the individual, ensuring the best outcomes while minimising adverse reactions that can be Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi, said: 'The inclusion of APOE E4 genotyping in PGx report reflects our commitment to providing the best-in-class care for our communities through genetic profiling and precision therapies. This re-affirms Abu Dhabi's position as a global leader in healthcare innovation, driven by genomics-based healthcare solutions. Our goal is to provide clinicians with the most up-to-date and actionable genetic insights. These insights can be integrated into treatment plans, especially for therapies involving anti-amyloid monoclonal antibodies, to ensure safer and more effective care.'The pharmacogenomics reports initiative is part of the Emirati Genome Programme (EGP), which is building a comprehensive genetic database to support tailored treatments for EGP participants. PGx reports are securely available to all physicians in Abu Dhabi through Malaffi, DoH's health information a transformative milestone, 160,000 PGx reports are now available, a scale that surpasses many population genomics application programmes globally. This achievement will set a new standard for population genomics. Dr Fahed Al Marzooqi, Chief Executive Officer of Integrated Health Solutions at M42, said, 'The integration of pharmacogenomics into clinical care marks a transformative step towards precision medicine in Abu Dhabi. By embedding these insights directly into patient records, we are equipping healthcare providers with actionable data to enhance treatment safety and efficacy. This initiative, led by the Department of Health – Abu Dhabi, is made possible through M42's advanced health technology infrastructure, ensuring that every patient receives care that is tailored to their unique genetic makeup." "This milestone reaffirms Abu Dhabi's commitment to innovation in medicine and to putting patients at the centre of healthcare transformation. Currently, the reports are available for patients with specific conditions, including cancer, mental health disorders, respiratory illnesses, gastrointestinal issues, cardiovascular diseases, and infectious diseases, neurological diseases, pain management and now Alzheimer's," Al Marzooqi said. The Department of Health - Abu Dhabi and M42's Biogenix Lab are committed to regularly updating pharmacogenomics tools to reflect the latest scientific developments, ensuring continuous improvements in patient care.
Sharjah 24
15-04-2025
- Health
- Sharjah 24
Khaled bin Mohamed attends opening ceremony of ADGHW 2025
The event is organised by the Department of Health - Abu Dhabi under the theme 'Towards Longevity: Redefining Health and Wellbeing' and is taking place until 17 April at ADNEC Centre Abu Dhabi. The ceremony featured an address by Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, cultural and musical performances by Emirati talent, and an immersive experience that combined performance and technology to tell a powerful story about longevity and how good health can create a future filled with hope for individuals and nations alike. An opening panel set the scene for the event, exploring precision health in shaping a healthier and more sustainable future, health system resilience and sustainability, and the role of AI and digital health. Participants included Dr. Peter Attia, a physician, author and leading researcher dedicated to longevity medicine; Leymah Gbowee, founder and president of Gbowee Peace Foundation Africa and Nobel Peace Prize winner; and Peng Xiao, Group CEO of G42. Following the ceremony, H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan toured the exhibition to review healthcare innovations presented by more than 150 exhibitors from 90 countries. His Highness Sheikh Khaled bin Mohamed emphasised the significance of Abu Dhabi Global Health Week in highlighting various aspects of health by showcasing promising solutions and innovative developments that contribute to fostering communities' wellbeing globally. He also reaffirmed that hosting this global event reflects Abu Dhabi's commitment to staying ahead of emerging healthcare trends and opportunities, particularly with this year's focus on longevity and healthy living. His Highness Sheikh Khaled bin Mohamed bin Zayed highlighted that this requires the launch of initiatives and the implementation of programmes designed to advance medical and therapeutic research, as well as increase investment in advanced technologies and infrastructure, underscoring the emirate's unique ability to transform promising ideas into tangible solutions in the healthcare sector. Mansoor Ibrahim Al Mansoori said, 'Under the directives of our wise leadership, Abu Dhabi Global Health Week reflects Abu Dhabi's ambitious vision to transform health and ensure communities enjoy long, healthy lives by establishing an open and inclusive platform that brings all stakeholders together to enhance health outcomes. The event stands as a borderless community dedicated to advancing the future of health and wellbeing through a proactive approach centred around preventive, personalised, and holistic care.' ADGHW 2025 will welcome more than 200 speakers, 15,000 visitors and 1,900 delegates over three days. The event will feature healthcare leaders, pioneers and changemakers from around the world, including global health and policy leaders. At the core of this year's edition is the Forum @ ADGHW, a global stage uniting leaders from government, industry, research and academia to tackle critical healthcare challenges. Additionally, the StartUp Zone will serve as a hub for collaboration and innovation, inviting startups to pitch their innovative ideas to investors, with winners of the Smart Health Hackathon announced during the event. By supporting initiatives like the Smart Health Hackathon, ADGHW seeks to provide emerging entrepreneurs and innovators with an opportunity to showcase their innovations and connect with experts and investors. The winners of the prestigious ADGHW Innovation Awards will also be announced, in celebration of individuals and organisations driving innovation and collaboration, fostering a culture of excellence that will shape the future of health. ADGHW is a major government initiative from the Department of Health and Abu Dhabi and serves as a platform for innovation and collaboration. The event places a strong emphasis on community-driven health and wellbeing, with a proactive approach centred around preventive, personalised, and holistic care. ADGHW 2025 covers key themes including longevity and precision health, health system resilience, digital health, and investment in life sciences.
Khaleej Times
15-04-2025
- Health
- Khaleej Times
Mediclinic Middle East to participate in Abu Dhabi Global Health Week
Mediclinic subject matter experts will share their views on key issues affecting the healthcare sector Mediclinic Middle East has announced its participation in Abu Dhabi Global Health Week, set to take place from 15-17 April 2025. Mediclinic is one of the UAE's leading private healthcare providers with seven hospitals and a community network of 29 outpatient and day surgery clinics across Abu Dhabi, Al Ain and Dubai. It offers a range of market-leading primary, secondary and tertiary healthcare services including international standard cancer care, robotic surgery, kidney transplantation, IVF, genetic testing and holistic women's healthcare, amongst others. We are looking forward to supporting the event's hosts, the Department of Health - Abu Dhabi, as they lead the way in fostering a sustainable healthcare system and advancing the shift from care to prevention. Abu Dhabi Global Health Week is a premier international gathering that brings together policymakers, industry leaders and innovators to shape the future of healthcare, and Mediclinic is excited to enter the dialogue and contribute to crucial discussions on the most important issues. During the event, Mediclinic's subject matter experts will present at the Mediclinic stand on a range of key topics including: The Digital Health Revolution - Ahmad Awada, Divisional General Manager Digital Health Transformation & Innovation Medical Tourism - Victoria Sander-Perrin, Director of Sales Benefits of Public Private Sector Partnership in Academia – Dr Adrian Stanley, Chief Academic Officer Transforming Radiology: Driving Innovation and Advancing Healthcare - Dr Ramzy Ross, Director Shared Clinical Services Transformation and Innovation AI and Automation in Healthcare - Omar Schoenthaler, Director Data Science, and Raghu Tadikamalla, Group Automation Manager Mediclinic Approach to Cancer Care - Dr Mohanad Diab, Director Cancer Services, Abu Dhabi Wellness - Dr Jacques Kobersy, Chief Medical Officer Mediclinic will also be showcasing its revolutionary new digital health screening booth which offers instant, actionable insights into to users' wellbeing. Investment in this innovative technology demonstrates Mediclinic's position as a leader in preventive, tech-enabled healthcare and its commitment to driving population health and wellness through personalised, data-driven solutions. "Mediclinic has been proud to serve the Abu Dhabi and Al Ain population ever since entering this market in 2016 through the acquisition of the Al Noor Hospitals Group. Through investment in expansion projects, more details of which we will announce during Abu Dhabi Global Health Week, we are looking to further improve the level of healthcare for patients in Abu Dhabi, and we are committed to contributing to a healthier future by aligning with the forward-thinking initiatives of the Department of Health," said Hein van Eck, CEO of Mediclinic Middle East.
